/Lilly(Eli)%20%26%20Co%20logo%20on%20building-by%20Michael%20Vi%20via%20Shutterstock.jpg)
With a market cap of $775.6 billion, Eli Lilly and Company (LLY) is a global biopharmaceutical leader with leading products in diabetes (Trulicity, Mounjaro), oncology (Verzenio, Erbitux) and immunology (Taltz, Olumiant). Through strategic acquisitions such as ImClone Systems, ICOS Corporation, and Loxo Oncology and partnerships with Incyte, Boehringer Ingelheim and Innovent, Lilly sustains a robust pipeline despite patent cliffs and pricing pressures.
The Indianapolis, Indiana-based company is expected to release its fiscal Q1 2025 earnings results before the market opens on Thursday, May 1. Ahead of this event, analysts expect LLY to report an adjusted EPS of $4.44, up 72.1% from $2.58 in the prior year's quarter. It has surpassed Wall Street's bottom-line estimates in three of the past four quarters while missing on another occasion. In Q4 2024, Eli Lilly exceeded the consensus adjusted EPS estimate by 5.8%.
